BioCentury | Apr 14, 2014
Finance

Banker tracks

...officer at Biogen Idec Inc. (NASDAQ:BIIB) on May 15. Private equity tracks Kern Wildenthal joined Satori...
BioCentury | Nov 4, 2013
Company News

Theravance management update

...Gastrointestinal, Pulmonary Hired: Jeff Jonker as SVP of corporate and business development, formerly CBO of Satori Pharmaceuticals Inc. WIR...
BioCentury | Oct 25, 2012
Distillery Therapeutics

Indication: Neurology

...in the brain compared with vehicle control. Next steps include safety studies on similar compounds. Satori Pharmaceuticals Inc....
...et al. J. Exp. Med.; published online Oct. 3, 2012; doi:10.1021/jm300976b Contact: Jed L. Hubbs, Satori Pharmaceuticals Inc....
BioCentury | Sep 13, 2012
Targets & Mechanisms

This is (a diagnostic) spinal tap

...of motor symptoms in PD-and thus guide treatment decisions, he said. Barbara Tate, VP at Satori Pharmaceuticals Inc....
...behavior is often used to measure cognition, said Jo Ann Dumin, principal research investigator at Satori...
...patient population, that could save a lot of time and money," she said. This year, Satori...
BioCentury | Feb 27, 2012
Financial News

Satori completes venture financing

...Venture financing Raised: $15 million Investors: InterWest Partners; New Enterprise Associates; Prospect Venture Partners Note: Satori...
BioCentury | Feb 27, 2012
Finance

Bridge to acquisition

...Bridge to acquisition First generation gamma secretase inhibitors didn't work in Alzheimer's disease, but Satori Pharmaceuticals Inc. is...
...more selective gamma secretase modulator will not have the toxicity of previous compounds. Last week, Satori...
...two other existing investors: New Enterprise Associates and Prospect Venture Partners. InterWest started investing in Satori...
BioCentury | Feb 27, 2012
Company News

Satori board of directors update

Satori Pharmaceuticals Inc. , Cambridge, Mass. Business: Neurology Appointed: Donald Hayden, a director, as chairman; Stephen Muniz, partner at PureTech Ventures; and David Schnell, co-founder and managing director of Prospect Venture Partners WIR Staff Neurology...
BioCentury | Feb 24, 2012
Financial News

Satori raises $15 million

...Alzheimer's disease company Satori Pharmaceuticals Inc. (Cambridge, Mass.) raised $15 million in a financing co-led by existing investors...
...a financing co-led by existing investors InterWest Partners; New Enterprise Associates; and Prospect Venture Partners. Satori...
...Stephen Muniz and Prospect Venture's David Schnell joined Satori's board. PureTech is an existing investor. Satori...
BioCentury | Oct 24, 2011
Product Development

Alzheimer's rewind

...less toxic or perhaps beneficial, including beta amyloid 38, 39 and 40. This is what Satori Pharmaceuticals Inc....
...itself without affecting the whole pool" of other gamma secretase substrates, said CEO Jeff Ives. Satori...
...secretase. This may mean other gamma secretase substrates are likely to be left undisturbed by Satori's...
BioCentury | Oct 10, 2011
Finance

Venture's stress

...1999 Acquired by Daiichi-Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) for an undisclosed amount in Dec 2010 Satori Pharmaceuticals Inc....
Items per page:
1 - 10 of 19
BioCentury | Apr 14, 2014
Finance

Banker tracks

...officer at Biogen Idec Inc. (NASDAQ:BIIB) on May 15. Private equity tracks Kern Wildenthal joined Satori...
BioCentury | Nov 4, 2013
Company News

Theravance management update

...Gastrointestinal, Pulmonary Hired: Jeff Jonker as SVP of corporate and business development, formerly CBO of Satori Pharmaceuticals Inc. WIR...
BioCentury | Oct 25, 2012
Distillery Therapeutics

Indication: Neurology

...in the brain compared with vehicle control. Next steps include safety studies on similar compounds. Satori Pharmaceuticals Inc....
...et al. J. Exp. Med.; published online Oct. 3, 2012; doi:10.1021/jm300976b Contact: Jed L. Hubbs, Satori Pharmaceuticals Inc....
BioCentury | Sep 13, 2012
Targets & Mechanisms

This is (a diagnostic) spinal tap

...of motor symptoms in PD-and thus guide treatment decisions, he said. Barbara Tate, VP at Satori Pharmaceuticals Inc....
...behavior is often used to measure cognition, said Jo Ann Dumin, principal research investigator at Satori...
...patient population, that could save a lot of time and money," she said. This year, Satori...
BioCentury | Feb 27, 2012
Financial News

Satori completes venture financing

...Venture financing Raised: $15 million Investors: InterWest Partners; New Enterprise Associates; Prospect Venture Partners Note: Satori...
BioCentury | Feb 27, 2012
Finance

Bridge to acquisition

...Bridge to acquisition First generation gamma secretase inhibitors didn't work in Alzheimer's disease, but Satori Pharmaceuticals Inc. is...
...more selective gamma secretase modulator will not have the toxicity of previous compounds. Last week, Satori...
...two other existing investors: New Enterprise Associates and Prospect Venture Partners. InterWest started investing in Satori...
BioCentury | Feb 27, 2012
Company News

Satori board of directors update

Satori Pharmaceuticals Inc. , Cambridge, Mass. Business: Neurology Appointed: Donald Hayden, a director, as chairman; Stephen Muniz, partner at PureTech Ventures; and David Schnell, co-founder and managing director of Prospect Venture Partners WIR Staff Neurology...
BioCentury | Feb 24, 2012
Financial News

Satori raises $15 million

...Alzheimer's disease company Satori Pharmaceuticals Inc. (Cambridge, Mass.) raised $15 million in a financing co-led by existing investors...
...a financing co-led by existing investors InterWest Partners; New Enterprise Associates; and Prospect Venture Partners. Satori...
...Stephen Muniz and Prospect Venture's David Schnell joined Satori's board. PureTech is an existing investor. Satori...
BioCentury | Oct 24, 2011
Product Development

Alzheimer's rewind

...less toxic or perhaps beneficial, including beta amyloid 38, 39 and 40. This is what Satori Pharmaceuticals Inc....
...itself without affecting the whole pool" of other gamma secretase substrates, said CEO Jeff Ives. Satori...
...secretase. This may mean other gamma secretase substrates are likely to be left undisturbed by Satori's...
BioCentury | Oct 10, 2011
Finance

Venture's stress

...1999 Acquired by Daiichi-Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) for an undisclosed amount in Dec 2010 Satori Pharmaceuticals Inc....
Items per page:
1 - 10 of 19